Chemistry:Mifomelatide
From HandWiki
Mifomelatide (INN; developmental code name TCMCB07) is a melanocortin MC3 and MC4 receptor antagonist which is under development for the treatment of cachexia.[1][2][3][4] It is a synthetic cyclic peptide and is taken by subcutaneous injection.[1][3] Mifomelatide crosses the blood–brain barrier.[3][4] The drug is being developed by Endevica Bio.[1][2] As of February 2025, it is in phase 2 clinical trials.[1][2]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "TCMCB 07". 27 December 2024. https://adisinsight.springer.com/drugs/800063197.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Mifomelatide with Synapse". 23 January 2025. https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/b74e4fedfd834b23be668d9891ffaf0c.
- ↑ 3.0 3.1 3.2 "Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 43 (43). June 2023. doi:10.1200/EDBK_389942. PMID 37290034.
- ↑ 4.0 4.1 "Advances in pharmacotherapies in cancer-related cachexia". Oncology and Translational Medicine 9 (1): 15–21. 2023. doi:10.1007/s10330-022-0611-1. ISSN 2095-9621. https://www.researchgate.net/publication/381484381.
 |  |
